Immunotherapy drives mesenchymal tumor cell state shift and TME immune response in glioblastoma patients.

ABSTRACT:

Background

Glioblastoma is a highly aggressive type of brain tumor for which there is no curative treatment available. Immunotherapies have shown limited responses in unselected patients, and there is an urgent need to identify mechanisms of treatment resistance to design novel therapy strategies.

Methods

Here we investigated the phenotypic and transcriptional dynamics at single-cell resolution during nivolumab immune checkpoint treatment of glioblastoma patients.

Results

We present the integrative paired single-cell RNA-seq analysis of 76 tumor samples from patients in a clinical trial of the PD-1 inhibitor nivolumab and untreated patients. We identify a distinct aggressive phenotypic signature in both tumor cells and the tumor microenvironment in response to nivolum

SUBMITTER: Hendriksen JD 

PROVIDER: S-EPMC11300009 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature